Exelixis: The Double Backbone Potential Of CABOMETYX And Zanzalintinib

Exelixis is being framed as a multi-franchise oncology company, with CABOMETYX providing durable cash flow and zanzalintinib highlighted as a growth driver with peak sales potential of $5B by 2033. The company’s 2026 revenue guidance of $2.52B-$2.62B excludes any contribution from zanzalintinib, suggesting upside optionality if the pipeline performs. Continued R&D investment and share repurchases support a constructive outlook.

Analysis

EXEL is transitioning from a single-asset cash-flow story to a two-engine valuation setup, and that matters because the market typically rerates oncology names not on absolute revenue but on the durability of the second franchise. The key second-order effect is that a credible next-line asset reduces the probability that CABOMETYX gets capitalized as a melting-ice-cube cash cow; instead, repurchases and elevated R&D become signs of optionality rather than underinvestment. That should tighten the equity risk premium and support multiple expansion before the new product fully contributes.

The competitive read-through is less about one drug versus one drug and more about timing: any delay in the emerging franchise disproportionately helps larger oncology platforms with broader combo infrastructure, trial execution, and payer leverage. If zanzalintinib lands as expected, the most vulnerable peers are mid-cap oncology companies relying on a single growth driver, because EXEL would become a cleaner capital allocator with a stronger internal funding loop for pipeline expansion. Supply-chain exposure is limited, but CROs and oncology trial vendors could see incremental demand if management presses R&D harder to defend growth.

The main risk is that the market may be pricing in the new franchise too early while underestimating execution slippage. Over the next 6–18 months, the stock will likely trade on clinical/regulatory inflection points rather than 2033 peak-sales math; any trial readout or label ambiguity can compress the multiple quickly because the valuation already implies a meaningful probability of success. On the flip side, the cash return program limits downside on disappointment, making this a lower-volatility way to express oncology pipeline upside than many pre-commercial peers.

Consensus may be missing that buybacks are not just capital return here — they can be a signaling device that management believes the core base business is underappreciated and that the next leg of growth will be funded without balance-sheet strain. The underappreciated bull case is a multiple rerate driven by franchise breadth before revenue inflects, not after. In that scenario, the stock can outperform on narrative shift alone, while the actual earnings bridge arrives later.

Key Decisions for Investors

• Go long EXEL on any post-rally consolidation over the next 2-6 weeks; the favorable risk/reward is a rerating trade, not a near-term earnings beat, with upside tied to increased confidence in the second franchise.
• Use call spreads on EXEL with 6-12 month tenor to express pipeline optionality while limiting premium burn; this is preferable to outright stock if you want defined downside ahead of clinical catalysts.
• Pair long EXEL vs short a mid-cap oncology single-asset name over 3-9 months; EXEL has better balance between cash generation and pipeline optionality, so it should de-risk faster if biotech sentiment weakens.
• If EXEL rallies into peak-sales optimism without a data catalyst, trim 25-30% and wait for a pullback; the market can over-advance the zanzalintinib story well before de-risking events occur.
• Watch for any accelerated buyback cadence as a signal to increase position size; continued repurchases would support a floor under the shares and indicate management sees the current multiple as too low.